Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab-Reference-Cited by-同舟云学术

Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab

Published:2022-03 Issue:3 Volume:4 Page:e198-e207
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Strand Vibeke,O’Quinn Sean,Furie Richard A,Morand Eric F,Kalunian Kenneth C,Schwetje Erik G,Abreu Gabriel,Tummala Raj

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference31 articles.

1. Systemic lupus erythematosus;Kaul;Nat Rev Dis Primers,2016

2. Burden of systemic lupus erythematosus on employment and work productivity: data from a large cohort in the southeastern United States;Drenkard;Arthritis Care Res (Hoboken),2014

3. Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performance;Holloway;Health Qual Life Outcomes,2014

4. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort;Bruce;Ann Rheum Dis,2015

5. Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999–2014);Jorge;Rheumatology (Oxford),2018

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients with NPSLE experience poorer HRQoL and more fatigue than SLE patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activity;Rheumatology;2024-04-05

2. The Type 1 & 2 systemic lupus erythematosus model: Perspectives of people living with systemic lupus erythematosus;Lupus;2024-01-18

3. Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials;Expert Opinion on Emerging Drugs;2023-04-03

4. A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus;Arthritis & Rheumatology;2022-11-11

5. Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature;Autoimmunity Reviews;2022-11